172 related articles for article (PubMed ID: 37039257)
1. Molecular profiling of colorectal cancer in a genetically admixed Hispanic population.
Montes-Rodríguez IM; Centeno-Girona H; Rivera-Lynch C; Rivera N; Cruz-Correa M
Cancer Med; 2023 May; 12(10):11686-11702. PubMed ID: 37039257
[TBL] [Abstract][Full Text] [Related]
2. Molecular and Sociodemographic Colorectal Cancer Disparities in Latinos Living in Puerto Rico.
Perez-Mayoral J; Gonzalez-Pons M; Centeno-Girona H; Montes-Rodríguez IM; Soto-Salgado M; Suárez B; Rodríguez N; Colón G; Sevilla J; Jorge D; Llor X; Xicola RM; Toro DH; Tous-López L; Torres-Torres M; Reyes JS; López-Acevedo N; Goel A; Rodríguez-Quilichini S; Cruz-Correa M
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107652
[TBL] [Abstract][Full Text] [Related]
3. Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study.
Baba O; Bidikian A; Mukherji D; Shamseddin A; Temraz S; Fakhruddin N; Khazzouh M; Ghizzawi D; Abdel Khalek R; Zaatari G; Mahfouz R
Gene; 2022 Aug; 834():146646. PubMed ID: 35680020
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients.
Dong Z; Kong L; Wan Z; Zhu F; Zhong M; Lv Y; Zhao P; Shi H
Sci Rep; 2019 Nov; 9(1):16894. PubMed ID: 31729406
[TBL] [Abstract][Full Text] [Related]
5. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.
He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M
World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873
[TBL] [Abstract][Full Text] [Related]
6. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer.
Guo Y; Guo XL; Wang S; Chen X; Shi J; Wang J; Wang K; Klempner SJ; Wang W; Xiao M
Oncologist; 2020 Nov; 25(11):e1671-e1680. PubMed ID: 32627883
[TBL] [Abstract][Full Text] [Related]
7. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of
Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
[TBL] [Abstract][Full Text] [Related]
10. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
11. The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
Costigan DC; Dong F
Genes Chromosomes Cancer; 2020 Mar; 59(3):152-159. PubMed ID: 31589789
[TBL] [Abstract][Full Text] [Related]
12. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
13. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
[TBL] [Abstract][Full Text] [Related]
16. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
17. Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico.
De Jesus-Monge WE; Gonzalez-Keelan C; Zhao R; Hamilton SR; Rodriguez-Bigas M; Cruz-Correa M
Fam Cancer; 2010 Jun; 9(2):155-66. PubMed ID: 20012372
[TBL] [Abstract][Full Text] [Related]
18. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
19. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
20. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]